Piper Sandler initiated coverage of Viking Therapeutics (VKTX) with an Overweight rating and $74 price target The company has generated one of the more compelling weight loss profiles in Phase 2 with VK2735 in conjunction with lower discontinuation rates in obese patients, the analyst tells investors in a research note. Piper also thinks Viking has a potentially “best” oral incretin with oral VK2735 which has observed lower rates of adverse events and competitive efficacy relative to other incretins currently in development.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- Viking’s VK2735 outpacing Amgen’s MariTide, says H.C. Wainwright
- Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards
- Viking Therapeutics initiated with a Buy at B. Riley
- Viking Therapeutics reports results from Phase 2b clinical trial of VK2809
- Viking to present data from Phase 2b VOYAGE study in late breaker presentation
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
